Tweets
Small study 34 biologic-naive RA pts starting abatacept. Remission achieved 47.1% of early and 23.5% established RA. Remission @ 6 mos predicted by Baseline LOWER IL-6 levels ≤ 8.4 pg/ml, (66.7%) and CD4+CD25+FoxP3+ cells ≥ 6% (83.3%) https://t.co/N93E9M4M15
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
There are 494K PCPs in the USA, While up to 1/3 will "refill" DMARDs, only 6-9% are confident or knowledgeable in "initiating" DMARD therapy in #RA. GIGANTIC NEED FOR PCP education in MSK & Rheum Dz https://t.co/VjgWWDt3nX https://t.co/dTRXxsrzG5
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
OA Initiative Study of 1212 knee OA pts (age 63 yrs), 73% walked for exercise. Walkers had signif. less New frequent knee pain (OR 0.6) & medial joint space narrowing (OR 0.8). Walking for exercise should be encouraged in knee OA pts. https://t.co/MLs9zutdRd
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Watch: Fatigue and Central Sensitization in Rheumatic Disease -
We're sharing Philip Mease, MD presentation from the RheumNow Live 2022 meeting held in March.
https://t.co/SFzsszL1aM https://t.co/DkxVPim9iU
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Learn how clinical research targeting immune pathways can help reduce the burden of #psoriaticarthritis symptoms, such as joint pain, stiffness, and swelling, as well as fatigue: https://t.co/ReBQVyYVka Sponsored by Janssen @JanssenUS https://t.co/fRb6kAj848
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Study of interferon (IFN) gene signature (IGS) finds IGS elevated in half of early RA pts; high IGS portends higher DAS28, fewer EULAR good resp & higher IFN-α; the latter assoc w/ epigentic changes, more lymphoctye activation. IFN-α as a biomarker? https://t.co/BHC98OR30A https://t.co/SRE7KVaoha
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Yesterday the FDA approved baricitinib (Olumiant) as the first systemic treatment for Alopecia Areata. Approval based on 2 DBRPCT Trial AA-1, AA-2) - 32% & 35% of pts on Bari 4 mg regrew scalp hair coverage by wk 36. https://t.co/SU74OxI2BC https://t.co/2wluug1fj4
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
450 axSpA pts followed 2868 Pt-yrs, 48% on TNFis. TNFi Rx pts had reduced CV risk (HR 0.30; 0.10–0.85), but no longer signif after adjustment for CRP, ESR (HR 0.37, 0.12–1.12, p = 0.077). Reduced CV risk, may not be specifically due to TNFi use https://t.co/mVHYn3PteL https://t.co/bgKWreBL8z
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok.
https://t.co/pom5KD0qt7 https://t.co/djYHZ5LdcE https://t.co/47lfyZC4H3
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Watch: The Microbiome in Spondyloarthritis
Can microbes trigger SpA/PsA?
https://t.co/KN7dMFU9qo https://t.co/k3M5QfwqGp
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Cluster study of 383 aPL+ pts showed 4 clusters:
Cluster 1 (138): w/ SLE & non-criteria Sxs
Cluster 2 (112): pts w/ CV risks
Cluster 3 (83): females w/ OB morbidity (BEST outcome)
Cluster 4 (50): lupus anticoagulant (+) (high freq of arterial thrombosis) https://t.co/HGRTceplsn https://t.co/ZDdwhCmj5r
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
GLORIA Study Pred vs PBO in >65yrs RA x 2 years. 451 Pts & DAS28 4.5. 79% on DMARDs (14% biologics)
Upside: Lower DAS28 -0.37 & less Xray progression -1.7 Sharp units
Downside: 24% more AE (mild infxns), signif.small lowering of lumbar BMD -1%
You Decide
https://t.co/RRq0WcFsXz https://t.co/xLxjPPSMhh
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
